Abstract

Chronic kidney disease (CKD) is a public health problem driven by myofibroblast accumulation, leading to interstitial fibrosis. Heterogeneity is a recently recognized characteristic in kidney fibroblasts in CKD, but the role of different populations is still unclear. Here, we characterize a proinflammatory fibroblast population (named CXCL-iFibro), which corresponds to an early state of myofibroblast differentiation in CKD. We demonstrate that CXCL-iFibro co-localize with macrophages in the kidney and participate in their attraction, accumulation, and switch into FOLR2+ macrophages from early CKD stages on. In vitro, macrophages promote the switch of CXCL-iFibro into ECM-secreting myofibroblasts through a WNT/β-catenin-dependent pathway, thereby suggesting a reciprocal crosstalk between these populations of fibroblasts and macrophages. Finally, the detection of CXCL-iFibro at early stages of CKD is predictive of poor patient prognosis, which shows that the CXCL-iFibro population is an early player in CKD progression and demonstrates the clinical relevance of our findings.

Fibroblast heterogeneity is a recognized feature in chronic kidney disease, and although fibrosis is integrant to the pathology, it is lesser known which of the fibroblast populations contribute. Here authors describe a population of proinflammatory fibroblasts, which are found in close proximity to macrophages and may facilitate their recruitment and acquisition of a FOLR2+, pathogenic phenotype.

Details

Title
WNT-dependent interaction between inflammatory fibroblasts and FOLR2+ macrophages promotes fibrosis in chronic kidney disease
Author
Cohen, Camille 1 ; Mhaidly, Rana 1 ; Croizer, Hugo 1 ; Kieffer, Yann 1   VIAFID ORCID Logo  ; Leclere, Renaud 2   VIAFID ORCID Logo  ; Vincent-Salomon, Anne 2   VIAFID ORCID Logo  ; Robley, Catherine 1 ; Anglicheau, Dany 3   VIAFID ORCID Logo  ; Rabant, Marion 4 ; Sannier, Aurélie 5 ; Timsit, Marc-Olivier 6 ; Eddy, Sean 7   VIAFID ORCID Logo  ; Kretzler, Matthias 8 ; Ju, Wenjun 8   VIAFID ORCID Logo  ; Mechta-Grigoriou, Fatima 1   VIAFID ORCID Logo 

 PSL Research University, Institut Curie, Stress and Cancer Laboratory, Equipe labélisée par la Ligue Nationale contre le Cancer, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645); Inserm, U830, Paris, France (GRID:grid.7429.8) (ISNI:0000 0001 2186 6389) 
 Institut Curie Hospital Group, Department of Diagnostic and Theragnostic Medicine, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
 Paris Cité University, Inserm U1151, Department of Nephrology and Kidney Transplantation, Necker Hospital, AP-HP, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602) 
 Paris Cité University, Department of Pathology, Necker Hospital, AP-HP, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602) 
 Paris Cité University, Inserm, U1148, Department of Pathology, AP-HP, Bichat-Claude Bernard Hospital, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389) 
 Paris Cité University, Department of Urology, Européen George Pompidou Hospital, APHP, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109) 
 University of Michigan, Department of Internal Medicine, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347) 
 University of Michigan, Department of Internal Medicine, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347); University of Michigan, Department of Computational Medicine and Bioinformatics, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000 0004 1936 7347) 
Pages
743
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2918403356
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.